keyword
MENU ▼
Read by QxMD icon Read
search

Testosterone therapy

keyword
https://www.readbyqxmd.com/read/28097272/erratum-correction-of-the-references-for-figures-testosterone-therapy-in-men-with-testosterone-deficiency-are-we-beyond-the-point-of-no-return
#1
Abdulmaged Traish
[This corrects the article on p. 384 in vol. 57.].
January 2017: Investigative and Clinical Urology
https://www.readbyqxmd.com/read/28093144/re-study-of-testosterone-guided-androgen-deprivation-therapy-in-management-of-prostate-cancer
#2
Samir S Taneja
No abstract text is available yet for this article.
February 2017: Journal of Urology
https://www.readbyqxmd.com/read/28081317/hormone-therapy-in-hypospadias-surgery-a-survey-on-the-current-practice-in-turkey
#3
Gülnur Göllü Bahadır, Ergun Ergün, Onur Telli, Farid Khanmammadov, Ahmet Murat Çakmak
BACKGROUND/AIM: Nowadays surgical intervention is possible in smaller phalluses and younger children with hypospadias disease. Different hormone treatments with different doses, modalities, indications, and treatment times come along with some disputes. The aim of this study is to evaluate the management approaches in hypospadias surgery of surgeons in regards to hormone preparations. MATERIALS AND METHODS: Questionnaires were sent via e-mail to 110 actively working pediatric surgeons and urologists...
December 20, 2016: Turkish Journal of Medical Sciences
https://www.readbyqxmd.com/read/28081039/hiv-and-hypogonadism-a-new-challenge-for-young-aged-and-middle-aged-men-on-effective-antiretroviral-therapy
#4
Marie Lachâtre, Armelle Pasquet, Faïza Ajana, Benoit Soudan, Georges Lion, Laurence Bocket, Pauline Cornavin, Eric Senneville, Faroudy Boufassa, Antoine Chéret
Male hypogonadism is poorly defined in people living with HIV. Using a reliable free-testosterone assay, we examined the prevalence and risk factors of male hypogonadism among people living with HIV on effective antiretroviral therapy. Male hypogonadism was found in 12.4% of patients, twice the rate reported in the general population of the same age. Two risk thresholds, namely 5 years of antiretroviral therapy and 19% total body fat, may help to identify patients at risk.
January 28, 2017: AIDS
https://www.readbyqxmd.com/read/28078224/impact-of-recent-fda-ruling-on-testosterone-replacement-therapy-trt
#5
Sarita O Metzger, Arthur L Burnett
No abstract text is available yet for this article.
December 2016: Translational Andrology and Urology
https://www.readbyqxmd.com/read/28078223/testosterone-therapy-and-prostate-cancer
#6
REVIEW
Alexander W Pastuszak, Katherine M Rodriguez, Taylor M Nguyen, Mohit Khera
The use of exogenous testosterone to treat hypogonadism in the men with a history of prostate cancer (CaP) remains controversial due to fears of cancer recurrence or progression. Due to the detrimental impact of hypogonadism on patient quality of life, recent work has examined the safety of testosterone therapy (TTh) in men with a history of CaP. In this review, we evaluate the literature with regards to the safety of TTh in men with a history of CaP. TTh results in improvements in quality of life with little evidence of biochemical recurrence or progression in men with a history of CaP, or de novo cancer in unaffected men...
December 2016: Translational Andrology and Urology
https://www.readbyqxmd.com/read/28078222/testosterone-replacement-therapy-and-the-heart-friend-foe-or-bystander
#7
REVIEW
David S Lopez, Steven Canfield, Run Wang
The role of testosterone therapy (TTh) in cardiovascular disease (CVD) outcomes is still controversial, and it seems will remain inconclusive for the moment. An extensive body of literature has investigated the association of endogenous testosterone and use of TTh with CVD events including several meta-analyses. In some instances, a number of studies reported beneficial effects of TTh on CVD events and in other instances the body of literature reported detrimental effects or no effects at all. Yet, no review article has scrutinized this body of literature using the magnitude of associations and statistical significance reported from this relationship...
December 2016: Translational Andrology and Urology
https://www.readbyqxmd.com/read/28078221/testosterone-replacement-therapy-and-voiding-dysfunction
#8
REVIEW
Wesley Baas, Tobias S Köhler
Testosterone replacement therapy (TRT) represents an increasing popular treatment option for men with late-onset hypogonadism (LOH). Because of unsubstantiated beliefs of testosterone's effect on the prostate, the FDA has recently placed a warning on testosterone products, stating that TRT may worsen benign prostatic hyperplasia (BPH). Within this review article we have demonstrated the current understanding of the physiology of testosterone and its relationship with prostatic and lower urinary tract physiology...
December 2016: Translational Andrology and Urology
https://www.readbyqxmd.com/read/28078220/hypogonadism-and-testosterone-replacement-therapy-in-end-stage-renal-disease-esrd-and-transplant-patients
#9
REVIEW
Grace Snyder, Daniel A Shoskes
Hypogonadism is a common problem in the end-stage renal disease (ESRD) and renal transplant population. It has widespread systemic effects and has been linked with mortality in dialysis patients and at the time of renal transplant. The etiology is likely multifactorial and most patients are afflicted by various comorbidities that can contribute to hypogonadism. Clinical manifestations are mostly nonspecific. We review the approach to the diagnosis of hypogonadism, focusing on both laboratory values and clinical signs and symptoms...
December 2016: Translational Andrology and Urology
https://www.readbyqxmd.com/read/28078219/hormone-therapy-for-transgender-patients
#10
REVIEW
Cécile A Unger
Many transgender men and women seek hormone therapy as part of the transition process. Exogenous testosterone is used in transgender men to induce virilization and suppress feminizing characteristics. In transgender women, exogenous estrogen is used to help feminize patients, and anti-androgens are used as adjuncts to help suppress masculinizing features. Guidelines exist to help providers choose appropriate candidates for hormone therapy, and act as a framework for choosing treatment regimens and managing surveillance in these patients...
December 2016: Translational Andrology and Urology
https://www.readbyqxmd.com/read/28078216/testosterone-replacement-therapy-role-of-pituitary-and-thyroid-in-diagnosis-and-treatment
#11
REVIEW
Megan Crawford, Laurence Kennedy
Crosstalk among hormones characterizes endocrine function, and assessment of the hypogonadal man should take that into consideration. In men for whom testosterone deficiency is a concern, initial evaluation should include a thorough history and physical exam in which other endocrinopathies are being considered. Hypogonadism can be associated with both pituitary and thyroid dysfunction, for which appropriate biochemical evaluation should be undertaken in certain clinical scenarios. If low serum testosterone is confirmed measurement of luteinizing and follicle stimulating hormones (LH and FSH respectively) is essential to establish whether the hypogonadism is primary or secondary...
December 2016: Translational Andrology and Urology
https://www.readbyqxmd.com/read/28078215/off-label-therapies-for-testosterone-replacement
#12
REVIEW
Lorenzo DiGiorgio, Hossein Sadeghi-Nejad
The incidence of hypogonadism has been steadily increasing over the last few years. Exogenous testosterone has been the standard treatment for hypogonadal men, but is associated with suppression of spermatogenesis as well as other possible adverse effects. There are other medications, currently considered "off label" for androgen replenishment, that exert their effect through modulation of the hypothalamic-gonadal axis. These medications increase endogenous testosterone levels and offer a different therapeutic approach...
December 2016: Translational Andrology and Urology
https://www.readbyqxmd.com/read/28078214/pharmacology-of-testosterone-replacement-therapy-preparations
#13
REVIEW
Jennifer J Shoskes, Meghan K Wilson, Michael L Spinner
The goal of testosterone replacement therapy (TRT) is to return serum testosterone levels to within physiologic range and improve symptoms in hypogonadal men. Some of the symptoms aimed to improve upon include decreased libido, erectile dysfunction, infertility, hot flashes, depressed mood, and loss of muscle mass or hair. Clinical use of testosterone for replacement therapy began approximately 70 years ago. Over the decades, numerous preparations and formulations have been developed primarily focusing on different routes of delivery and thus pharmacokinetics (PKs)...
December 2016: Translational Andrology and Urology
https://www.readbyqxmd.com/read/28078213/adult-onset-hypogonadism-evaluation-and-role-of-testosterone-replacement-therapy
#14
REVIEW
Andrew J Davidiuk, Gregory A Broderick
Testosterone deficiency (TD) has become a growing concern in the field of men's sexual health, with an increasing number of men presenting for evaluation of this condition. Given the increasing demand for testosterone replacement therapy (TRT), a panel of experts met in August of 2015 to discuss the treatment of men who present for evaluation in the setting of low or normal gonadotropin levels and the associated signs and symptoms of hypogonadism. This constellation of factors can be associated with elements of both primary and secondary hypogonadism...
December 2016: Translational Andrology and Urology
https://www.readbyqxmd.com/read/28078212/improvement-of-endothelial-function-following-initiation-of-testosterone-replacement-therapy
#15
Daniel A Shoskes, Barbara Tucky, Allan S Polackwich
BACKGROUND: Isolated recent studies have suggested an increased risk of heart attack as early as 3 months following testosterone replacement therapy (TRT). Such a rapid risk increase would likely require rapid deterioration of arterial endothelial function. Our goal was to assess arterial endothelial function in hypogonadal men prior to and at least 3 months after initiation of TRT. METHODS: Adult men were consented if they had symptoms of hypogonadism, a total testosterone <350 ng/dL, and planned to begin TRT...
December 2016: Translational Andrology and Urology
https://www.readbyqxmd.com/read/28078211/a-case-series-of-the-safety-and-efficacy-of-testosterone-replacement-therapy-in-renal-failure-and-kidney-transplant-patients
#16
Ahmad Majzoub, Daniel A Shoskes
BACKGROUND: Hypogonadism is common in patients with renal dysfunction and does not always correct following transplantation. Recent studies show increased mortality for dialysis and transplant patients with low testosterone (T). These patients are often not treated due to concerns over efficacy and complications (both real and imagined). There is surprisingly scant literature supporting the use of T therapy in these patients. We wished to examine the results of T therapy in our patients with renal failure or following transplant...
December 2016: Translational Andrology and Urology
https://www.readbyqxmd.com/read/28078210/testosterone-replacement-therapy
#17
Daniel A Shoskes, Lawrence S Hakim
No abstract text is available yet for this article.
December 2016: Translational Andrology and Urology
https://www.readbyqxmd.com/read/28053953/letter-to-the-editor-regarding-treatment-of-men-for-low-testosterone-a-systematic-review-by-huo-et-al-testosterone-replacement-therapy-toward-to-the-robust-evidence-and-facts
#18
COMMENT
Jae Hung Jung, Sang-Kuk Yang
No abstract text is available yet for this article.
December 2016: World Journal of Men's Health
https://www.readbyqxmd.com/read/28053949/effect-of-testosterone-replacement-therapy-on-cognitive-performance-and-depression-in-men-with-testosterone-deficiency-syndrome
#19
Hyun Jin Jung, Hong Seok Shin
PURPOSE: We aimed to evaluate the effect of testosterone replacement therapy (TRT) on cognitive function and depression in men with testosterone deficiency syndrome. MATERIALS AND METHODS: We carried out a prospective, placebo-controlled trial involving 106 men with total testosterone levels <3.3 ng/mL and symptoms of hypogonadism. Based on whether the patients received TRT (injection with 1,000 mg testosterone undecanoate) or a placebo (advice to modify lifestyle), the study population was divided into a TRT group (n=54) and a control group (n=52)...
December 2016: World Journal of Men's Health
https://www.readbyqxmd.com/read/28051040/pulsatile-gonadotropin-releasing-hormone-therapy-is-associated-with-earlier-spermatogenesis-compared-to-combined-gonadotropin-therapy-in-patients-with-congenital-hypogonadotropic-hypogonadism
#20
Jiang-Feng Mao, Zhao-Xiang Liu, Min Nie, Xi Wang, Hong-Li Xu, Bing-Kun Huang, Jun-Jie Zheng, Le Min, Ursula Brigitte Kaiser, Xue-Yan Wu
Both pulsatile gonadotropin-releasing hormone (GnRH) infusion and combined gonadotropin therapy (human chorionic gonadotropin and human menopausal gonadotropin [HCG/HMG]) are effective to induce spermatogenesis in male patients with congenital hypogonadotropic hypogonadism (CHH). However, evidence is lacking as to which treatment strategy is better. This retrospective cohort study included 202 patients with CHH: twenty had received pulsatile GnRH and 182 had received HCG/HMG. Patients had received therapy for at least 12 months...
December 27, 2016: Asian Journal of Andrology
keyword
keyword
7858
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"